ERBB2 and breast cancer: Indeed, we found reduction of BAK by shRNA led to loss of apoptotic activity of the combination in two HER2-amplified HCC-1419 and MDA-MB-453 breast cancer cell lines where we were able to achieve sufficient knockdown (Fig. 2A).